Lupin Limited - Fundamental Analysis 2026
- Analysis Date: September 12, 2026
- Exchange: NSE:LUPIN / BSE:500257
- Sector: Pharmaceuticals — US Generics, India Branded Formulations, Respiratory/Biosimilars, API
- Market Cap: Rs. 95,926 Cr (Large Cap)
Executive Summary
Fundamental Score: 7.7/10 ⭐⭐⭐⭐
Investment Recommendation: Buy
Conviction Level: High
Target Price: Rs. 2,500 (~19% upside) — 12-month horizon; Trendlyne consensus (36 analysts) ~Rs. 2,509, Nomura Rs. 2,580 (Buy), Motilal Oswal Rs. 2,500 (Neutral); note UBS holds an outlying Sell rating on GLP-1 competitive-risk grounds
Key Thesis: Lupin is the standout growth-plus-valuation combination among large-cap Indian pharma names covered in this sector report. FY26 revenue grew 23.9% to Rs. 27,958 Cr with EBITDA margin expanding sharply (23%→29% per Screener; 24.7%→33.6% per the company's own Rs. Mn-basis release) on a richer US complex-generics and respiratory mix, and net profit rose ~62% YoY to Rs. 5,355 Cr. This is now the 16th consecutive quarter of year-on-year growth, with Q1 FY27 revenue up 32-33% YoY driven by US sales (+42.9% YoY) and a re-accelerating India business (+13.9-15.1% YoY). Despite this, Lupin trades at just 16-18x trailing earnings — roughly half the multiple of Sun Pharma, Dr. Reddy's, or Cipla — after a ~13-17% pullback from its 52-week high, driven by a UBS sector downgrade citing US GLP-1 generic competitive risk and the July 2026 Trump administration phased-tariff announcement on generic drug imports. With ROE of 28.7% and ROCE near 30%, low leverage (D/E 0.29x), and a fast-improving free cash flow profile (FCF nearly quadrupled to Rs. 5,527 Cr in FY26), the valuation gap versus peers looks difficult to justify on fundamentals alone.
Business Overview
Company Profile:
Lupin Limited, founded by Dr. Desh Bandhu Gupta and headquartered in Mumbai, is an "innovation-led transnational pharmaceutical company" operating across generics, biosimilars, specialty brands, and APIs in 100+ countries. It is the 3rd largest player in the US by prescriptions (generics + total Rx) and the 8th largest company in the Indian Pharmaceutical Market (IPM), with global leadership positions in anti-TB and cephalosporin segments and strength in cardiovascular, diabetology, respiratory/asthma, pediatrics, and CNS therapies.
Business Model (FY26 revenue mix, Rs. Cr):
| Segment | FY26 Sales | YoY Growth | % of Total |
|---|---|---|---|
| United States | 11,678 | +46.0% | 42% |
| India | 8,114 | +7.1% | 30% |
| Other Developed Markets (EMEA, Japan, Australia, Canada) | 3,244 | +13.3% | 12% |
| Emerging/Growth Markets | 3,483 | +35.2% | 13% |
| API | 969 | -17.7% | 3% |
Q1 FY27 (June 2026 quarter) showed the same mix accelerating further: US +42.9% YoY, India +13.9% YoY, Other Developed Markets +48.3% YoY, Emerging Markets +51.7% YoY, API +8.5% YoY — total revenue +33.3% YoY.
US pipeline detail: 3rd largest generics player in the US by prescriptions; 149-151 generic products marketed; market leader in 56-61 marketed generics and top-3 in 112 products; 344-350 cumulative ANDA approvals out of 429-430 filed; 50-52 First-to-File filings (21-22 exclusive). Q1 FY27 alone saw 6 ANDA approvals and 3 new US launches.
Respiratory franchise: gSpiriva (tiotropium, FDA-approved 2023 — the first US generic of Boehringer Ingelheim's Spiriva HandiHaler), complex inhalation products mirroring Advair (fluticasone-salmeterol) and Pulmicort (budesonide), targeting the global inhaler market projected at >$45 Bn by 2027. In India: Budamate, Telekast, AB-Flo, Difizma (India's first Ultra LABA+LAMA+ICS), and Vilfuro-G (world's first fixed-dose triple DPI combination for COPD). Respiratory and diabetes therapies now >28% of branded-generics sales in regulated markets, up from <20% in FY21.
Biosimilars/specialty pivot: Lupin sold its US commercial women's-health specialty business (including Solosec) to Evofem Biosciences in July 2024 for up to $84 Mn in milestones, explicitly to refocus specialty efforts on respiratory and neurology. It then signed a global biosimilar Ranibizumab (anti-VEGF, wet AMD/DME) partnership with Sandoz (August 2025, covering EU ex-Germany, Switzerland, Norway, Australia, Hong Kong, Vietnam, Malaysia, with Lupin retaining manufacturing/regulatory filings) and an exclusive US licensing deal with Valorum Biologics (December 2025) for biosimilar pegfilgrastim ("Armlupeg"), under which Valorum commercializes in the US while Lupin manufactures/supplies and receives upfront fees plus royalties.
Market Position:
- 3rd largest US generics player by prescriptions; 8th largest player in the Indian Pharmaceutical Market
- Global leader in anti-TB and cephalosporin API/formulation segments
- Key competitors: Sun Pharma, Dr. Reddy's, Cipla, Aurobindo (US generics); Teva, Viatris (global generics); Sandoz, Biocon (biosimilars)
Competitive Moat:
- One of the largest ANDA pipelines among Indian pharma peers (429-430 filed, 344-350 approved), providing a broad, continuously-refreshing US launch cadence
- Differentiated respiratory/complex-inhalation manufacturing capability (gSpiriva as the first-to-market complex generic of its kind) — a genuine technical barrier versus simple oral-solid generics
- Strategic discipline in divesting non-core specialty assets (women's health) to concentrate R&D/manufacturing synergies in respiratory and biosimilars
Management Quality:
- Leadership: Vinita D. Gupta (CEO since September 2013, reappointed May 28, 2025); Nilesh Gupta (Managing Director since September 2023) — both children of founder Dr. Desh Bandhu Gupta; Ramesh Swaminathan (Executive Director, Global CFO & Head of API Plus SBU, reappointed March 26, 2025)
- Track Record: Successfully navigated Lupin from a steep FY22 loss year (US pricing pressure/one-off charges, EPS -Rs. 33.62) to sustained double-digit growth and margin expansion over the following four years — a genuine turnaround
- Concerns: Recent USFDA Form 483 observations across multiple facilities (see Risk Assessment) require continued management attention to compliance
Corporate Governance:
- Promoter Holding: 46.85% (marginally down from ~46.89% in prior quarters — gradual, minor open-market trimming, not a material red flag)
- Promoter Pledge: 0% currently. Historical note: in 2009, promoter entities Zyma Laboratories and Rahas Investments pledged a 12.60% stake, since fully released — no pledge exists today
- Institutional Support: FII 22.42%, DII 24.65% — strong combined institutional backing of ~47%
Financial Analysis
Revenue and Profit Trends
Annual Performance (Consolidated, Rs. Cr)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 |
| Operating Profit | 219 | 1,721 | 3,800 | 5,278 | 8,160 |
| OPM (%) | 1.3% | 10% | 19% | 23% | 29% |
| Net Profit | -1,528 | 448 | 1,936 | 3,306 | 5,355 |
| EPS (Rs.) | -33.62 | 9.45 | 42.01 | 71.88 | 116.65 |
FY22 was a steep loss year driven by US generics pricing pressure and one-off charges. The subsequent four-year recovery — 5-year sales CAGR 13%, 3-year profit CAGR ~140% off the FY22 trough — reflects a genuine operational turnaround, not merely an easy base-effect comparison, given the consistent sequential margin expansion each year since. Per the company's own FY26 press release (Rs. Mn basis), EBITDA margin reached 33.6% (up from 24.7% in FY25), R&D spend was Rs. 2,063 Cr (7.5% of sales), and a final dividend of Rs. 18/share (900% of face value) was recommended.
Quarterly Performance (Recent Quarters, Rs. Cr)
| Quarter | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Sales | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 |
| OPM (%) | 28% | 33% | 32% | 33% | 30-31% |
| Net Profit | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 |
Q1 FY27 (June 2026): Revenue Rs. 8,277 Cr (+32-33% YoY), EBITDA margin 31.4% (+210 bps YoY), Net Profit Rs. 1,417 Cr (+16.0% YoY) — the 16th consecutive quarter of YoY growth. R&D spend was Rs. 608 Cr (7.4% of sales). Management highlighted 7 new India brand launches and 6 ANDA approvals/3 new US launches during the quarter.
Margin Analysis
| Margin | FY24 | FY25 | FY26 | Trend | Peer Context |
|---|---|---|---|---|---|
| OPM | 19% | 23% | 29% | Sharply improving | Best margin trajectory in the sector — driven by US complex-generics/respiratory mix shift |
| Net Margin | 9.7% | 14.6% | 19.2% | Sharply improving | Approaching Sun Pharma/Cipla levels despite a much lower valuation |
Cash Flow Quality
| Metric | FY25 (Rs. Cr) | FY26 (Rs. Cr) | Assessment |
|---|---|---|---|
| Operating Cash Flow | 3,000 | 7,334 | More than doubled YoY |
| Free Cash Flow | 1,347 | 5,527 | Nearly quadrupled YoY |
| R&D Spend | — | 2,063 (7.5% of sales) | Consistent, healthy investment level |
Cash Flow Rating: 9/10 — the FY26 inflection in cash generation is one of the strongest in the sector this year
Balance Sheet Strength
| Metric | FY26 (Rs. Cr) | Analysis |
|---|---|---|
| Total Equity | ~22,448 | Growing quickly on retained earnings |
| Borrowings | 6,616 | Moderate |
| Debt-to-Equity | 0.29x | Low, comfortably manageable |
| Book Value/share | Rs. 491 | — |
| ROE | 28.7% | Best-in-class among sector large-caps |
| ROCE | 29.9-30% | Best-in-class among sector large-caps |
| Cash Conversion Cycle | 181 days | Elevated inventory days (303) partly offset by extended payables (208) |
Balance Sheet Rating: 8/10
Shareholding Pattern (India-Specific)
| Category | Jun 2026 | Trend | Assessment |
|---|---|---|---|
| Promoter Holding | 46.85% | Marginally declining | Stable majority-adjacent stake; minor open-market trimming, not a governance red flag |
| Promoter Pledge | 0% | — | Clean (2009 pledge fully released) |
| FII Holding | 22.42% | — | Solid |
| DII Holding | 24.65% | — | Solid |
Shareholding Rating: 7/10
Valuation
| Metric | Lupin | Sun Pharma | Dr. Reddy's | Cipla | Assessment |
|---|---|---|---|---|---|
| Current Price | Rs. 2,095-2,103 | Rs. 1,843 | Rs. 1,172 | ~Rs. 1,410 | — |
| Market Cap (Rs. Cr) | 95,926 | 4,42,245 | 97,854 | ~1,12,000 | Smallest of the four large-caps |
| PE Ratio | 16.1-18.0x | 35.0x | 30.3x | ~31x | Roughly half the multiple of every peer despite superior growth/returns |
| P/B | ~4.3x | — | ~2.58x | ~3.25x | Moderate |
| ROE | 28.7% | 16.0% | 11.2% | 11.6% | Best-in-class, by a wide margin |
| ROCE | 29.9-30% | 20.5% | 13.0% | 15.5% | Best-in-class, by a wide margin |
| D/E | 0.29x | 0.06x | 0.20x | 0.02x | Slightly higher than peers, still low in absolute terms |
| EV/EBITDA | ~11.2x | ~25x (est.) | ~16.1x (est.) | ~15x (est.) | Cheapest on this basis too |
| P/S | ~3.2x | ~7.2x (est.) | ~2.9x | ~3.9x | Comparable to Dr. Reddy's despite much stronger growth |
Valuation Verdict: CHEAP — Lupin combines the sector's best return ratios (ROE 28.7%, ROCE ~30%) and fastest recent growth/margin expansion with its cheapest valuation multiple. This is a genuine anomaly relative to the rest of the sector and appears substantially explained by the recent sentiment-driven pullback (UBS downgrade, tariff-announcement selloff) rather than any earnings deterioration — Q1 FY27 results were, if anything, described as record-setting.
Valuation Rating: 9/10
Fundamental Score: 7.7/10
| Criteria | Score | Rationale |
|---|---|---|
| Business Quality | 8/10 | 3rd largest US generics player by Rx, diversified across US/India/Other Developed/Emerging Markets, differentiated respiratory franchise, disciplined specialty pivot (divested women's health, added biosimilar licensing deals) |
| Financial Health | 9/10 | FY26 revenue +24%, net profit +62% YoY, EBITDA margin expanded from 23% to 29% (Screener basis), FCF nearly quadrupled to Rs. 5,527 Cr, low D/E 0.29x |
| Shareholding Pattern | 7/10 | Promoter 46.85% (marginal decline), 0% pledge, strong combined FII+DII (~47%) |
| Valuation | 9/10 | PE 16-18x vs. sector peers at 30-38x, despite the best ROE/ROCE in the group — the cheapest name in this sector report relative to quality |
| Growth Prospects | 8/10 | US momentum (+42.9% Q1 FY27), India re-acceleration (+13.9-15.1%), biosimilar licensing pipeline (Sandoz, Valorum), respiratory complex-generics runway; API segment still weak (-17.7% FY26) |
| Risk Management | 6/10 | Multiple recent USFDA Form 483 observations across facilities (Goa 7, Somerset 3, Pune 4, Indore 4, Ankleshwar 2) though none escalated to warning-letter/import-alert status; UBS-flagged GLP-1 competitive risk; long-dated US generic tariff threat |
Composite Score: 7.7/10
Investment Thesis
Bull Case (Target: Rs. 2,580 — ~23% upside, per Nomura)
- US momentum sustains as the complex-generics/respiratory mix continues expanding EBITDA margins toward global-peer levels
- India business re-acceleration (already +13.9-15.1% YoY in Q1 FY27) continues on new brand launches and chronic-therapy focus
- Sandoz (ranibizumab) and Valorum (Armlupeg pegfilgrastim) biosimilar licensing deals begin contributing meaningful royalty/milestone income
- Valuation re-rates back toward peer multiples (25-30x) as the market recognizes the disconnect between Lupin's superior growth/returns and its currently depressed PE
Bear Case (Target: Rs. 1,750 — ~-17% downside)
- UBS's GLP-1 competitive-risk thesis proves correct — US generic GLP-1 pricing collapses faster than expected as multiple players enter, eroding a key growth vector
- US Section 232-style tariffs on generic drug imports move from the current 0% (through 2028) toward escalation sooner than the stated phased timeline, given India's ~42% US revenue exposure
- A USFDA Form 483 observation (e.g., at Goa, which had the highest count at 7) escalates to a formal warning letter or import alert
- Margin expansion normalizes/reverses as the current elevated 29-33% OPM level was partly driven by a favorable, potentially temporary, US product mix
Base Case (Target: Rs. 2,500)
Growth continues at a more moderate but still healthy pace (India settles into low-teens growth, US growth moderates from the +42.9% Q1 FY27 pace but remains double-digit); the stock re-rates partially toward peer multiples as consensus estimates (Rs. ~2,509 average across 36 analysts) are met.
Expected Return Distribution:
- Bull Case (30% probability): +23% upside — Rs. 2,580
- Base Case (50% probability): +19% return — Rs. 2,500
- Bear Case (20% probability): -17% downside — Rs. 1,750
Risk Assessment
| Risk | Probability | Impact | Details |
|---|---|---|---|
| US GLP-1 Generic Competitive Risk | Medium | Medium-High | UBS specifically downgraded Lupin (alongside Dr. Reddy's, Zydus, Aurobindo) to Sell in 2026 citing exposure to a "highly competitive" US generic GLP-1 market with steep price cuts as multiple players enter — a real, sector-wide risk, not unique to Lupin |
| US Generic Tariff Escalation | Medium (long-dated) | High | Trump administration's phased plan: 0% tariff on generic imports through July 2028, then escalating to 100% (2028) and potentially 200% (2029) absent reshoring — Lupin's ~42% US revenue exposure and India-manufactured supply chain make this a genuine multi-year overhang, though the near-term (2026-2028) impact is nil |
| USFDA Facility Compliance | Medium | Medium | Recurring Form 483 observations across a broad multi-site network (Goa 7, Somerset NJ 3, Pune Biotech 4, Indore 4, Ankleshwar 2) and a Pithampur VAI classification (Jan 2026) — none have escalated to warning-letter/import-alert status as of September 2026, but the pattern across so many sites warrants continued monitoring |
| Ongoing Patent Litigation | Low-Medium | Low-Medium | Routine Paragraph IV litigation across 429-430 ANDA filings; the Astellas Myrbetriq dispute was settled in February 2026 (Lupin + Zydus paid a combined 150 Mn in upfront license payments to Astellas); a Novo Nordisk (Victoza/liraglutide) patent suit remains on record with status not fully confirmed |
| API Segment Weakness | Medium | Low | API revenue fell -17.7% in FY26 — a small (3% of sales) but persistently weak segment |
| Margin Sustainability | Medium | Medium | The sharp FY25→FY26 margin expansion (23%→29% OPM) reflects a favorable US product mix shift; durability of this mix at current levels is not yet proven over multiple years |
Overall Risk Rating: MEDIUM (6/10)
Catalysts
Near-term (0-3 months):
- Q2 FY27 results (October-November 2026) — watch whether the 30%+ OPM level and India re-acceleration are sustained
- Kotak Healthcare Conference (scheduled September 17, 2026) — management commentary on GLP-1 and tariff risk framing
Medium-term (3-12 months):
- Sandoz (ranibizumab) and Valorum (Armlupeg) biosimilar licensing deals beginning to contribute disclosed royalty/milestone revenue
- Continued US ANDA approval cadence (6 approvals/3 launches in Q1 FY27 alone) sustaining the launch pipeline
Long-term (1-3 years):
- Resolution of the US generic tariff framework (2028-2029 escalation schedule) and any manufacturing-footprint response
- Respiratory complex-generics franchise scaling further into the
>$45 Bn global inhaler market opportunity
Key Monitoring Parameters
Quarterly:
- India revenue growth sustainability (target: maintain low-teens+ YoY as seen in Q1 FY27's +13.9-15.1%)
- OPM trend (watch for stability at/above 29-30% vs. any reversion toward FY25's 23% level)
- Any escalation of USFDA Form 483 observations (particularly at Goa) toward warning-letter status
Trigger Events:
- ✅ Buy more: Valuation re-rates toward peer multiples while growth sustains; biosimilar licensing deals begin disclosed revenue contribution; no facility escalates to warning-letter status
- 🔻 Reduce/Exit: US GLP-1 generic pricing collapses faster than modeled (validating UBS's thesis); any USFDA warning letter/import alert; sharp India growth deceleration
Conclusion
Lupin presents the clearest valuation anomaly in this sector coverage: a business posting 16 consecutive quarters of YoY growth, the best ROE (28.7%) and ROCE (~30%) among large-cap Indian pharma peers, and a free cash flow profile that nearly quadrupled in FY26 — yet trading at roughly half the PE multiple of Sun Pharma, Dr. Reddy's, or Cipla following a sentiment-driven pullback (a UBS sector downgrade on GLP-1 competitive-risk grounds, plus the July 2026 US generic-tariff announcement). The underlying risks (GLP-1 pricing competition, long-dated tariff escalation, recurring but so-far-contained FDA facility observations) are real and worth monitoring, but none of them show up yet in the actual financial results, which remain the strongest in the sector. This combination of quality, growth, and a genuine valuation discount makes Lupin the highest-conviction Buy among the companies covered in this sector report.
Investment Recommendation: Buy Suitable For: Core long-term pharma sector exposure; both moderate and aggressive investors Portfolio Allocation: 4-6% of portfolio
Related Analyses
- Indian Pharma Sector Overview
- Sun Pharmaceutical Industries - Fundamental Analysis
- Dr. Reddy's Laboratories - Fundamental Analysis
- Cipla - Fundamental Analysis
- Divi's Laboratories - Fundamental Analysis
- Biocon - Fundamental Analysis
Disclaimer
This analysis is for educational and informational purposes only and does not constitute investment advice. Conduct your own due diligence and consult a qualified financial advisor before making investment decisions.
Data Sources
- Screener.in — Lupin consolidated financials, ratios, shareholding (Accessed September 11-12, 2026)
- Lupin Investor Relations (lupin.com press releases) — FY26 and Q1 FY27 results, segment revenue detail (Accessed September 11-12, 2026)
- Business Standard, BusinessToday, Eastern Herald — Quarterly results commentary, tariff-selloff coverage, UBS downgrade coverage (Accessed September 11-12, 2026)
- Trendlyne, Business Standard (Nomura), Investment Guru India (Motilal Oswal) — Analyst consensus and brokerage target prices (Accessed September 11-12, 2026)
- Medical Dialogues, Business Standard, BW Healthcare World, Investment Guru India — USFDA facility inspection history (Accessed September 11-12, 2026)
Data Timestamp: September 12, 2026 (Stock Price: ~Rs. 2,095-2,103, Market Cap: Rs. 95,926 Cr)
Next Update Recommended: After Q2 FY27 earnings (October-November 2026) or any material USFDA facility status change